Erector Spinae vs Intercostal Nerve Blocks for Pain in Thoracic Surgery
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two methods for managing pain after thoracic surgery, such as lung or chest wall surgeries. It compares the effectiveness of an erector spinae block, which uses bupivacaine, with an intercostal nerve block that uses a longer-lasting form of bupivacaine. Individuals who have undergone video-assisted lung surgery or similar procedures and do not have allergies to local anesthetics may be suitable candidates. The trial aims to determine which method provides better pain relief after surgery. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to potentially groundbreaking pain management solutions.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
A previous study found that using erector spinae blocks with bupivacaine was safe. Patients experienced less pain and required fewer strong painkillers. This method also reduced nausea and vomiting after surgery.
Research has shown that intercostal nerve blocks with liposomal bupivacaine are safe and provide effective pain relief post-surgery. One study found that this type of block managed pain well without major side effects.
Both treatments aim to control pain effectively and safely. Evidence suggests they are well-tolerated by patients.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because they offer new ways to manage pain after thoracic surgery. The erector spinae block (ESB) uses bupivacaine (Marcaine®) and targets the nerves in the back near the spine, potentially providing broader pain relief with fewer side effects compared to traditional intercostal nerve blocks. The intercostal nerve block (INB) in this study uses liposomal bupivacaine (Exparel®), which is designed to release the medication slowly, possibly extending pain relief and reducing the need for opioids. Both approaches aim to enhance recovery by managing pain more effectively and safely.
What evidence suggests that this trial's treatments could be effective for pain in thoracic surgery?
This trial will compare the effectiveness of two pain management techniques for thoracic surgery: the Erector Spinae Block (ESB) with Bupivacaine and the Intercostal Nerve Block (INB) with Liposomal Bupivacaine. Studies have shown that bupivacaine in an erector spinae block can reduce pain after chest surgery. While effective for pain relief, some patients may still experience moderate to severe pain. In contrast, intercostal nerve blocks with liposomal bupivacaine have proven very effective. Research indicates that this treatment can significantly reduce pain and help patients recover faster by enabling earlier movement after surgery. Both treatments offer promising options for managing pain after chest surgery.23467
Are You a Good Fit for This Trial?
This trial is for individuals undergoing thoracic surgery, specifically video-assisted pulmonary resection, pleurodesis or decortication. It's not suitable for those who may have conditions that exclude them from the study as per the detailed criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preoperative
Participants receive either an erector spinae block or an intercostal nerve block before surgery
Postoperative
Participants are monitored for pain management efficacy using morphine equivalent assessment and pain scores
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Erector Spinae Block with Bupivacaine (Marcaine®)
- Intercostal Nerve Block
Find a Clinic Near You
Who Is Running the Clinical Trial?
George Washington University
Lead Sponsor